

From: [REDACTED]
To: [GALLINA Sandra \(SANTE\)](#); [JORNA Kerstin \(GROW\)](#); [WEYAND Sabine \(TRADE\)](#); [\[REDACTED\]@ec.europa.eu](#)
Cc: [REDACTED]
Subject: EFPIA and Vaccines Europe technical elements regarding Regulation 2021/111
Date: lundi 15 février 2021 17:50:13
Attachments: [EFPIA_VE Communication_Export measures_15022021.docx](#)

Dear Director Generals,

I hope this email finds you well in these challenging times.

Further to the letter of 12 February addressed to Executive Vice-President Dombrovskis and Commissioners Breton and Kyriakides, I am writing to you on behalf of EFPIA and Vaccines Europe to share the attached document regarding Regulation 2021/111 and its practical implementation, for your kind consideration.

Thank you in advance for your time and attention.

[REDACTED] EFPIA and Vaccines Europe

[REDACTED]
[REDACTED]

EFPIA - European Federation of Pharmaceutical Industries and Associations
Leopold Plaza Building
Rue du Trône 108
B-1050 Bruxelles

[REDACTED]
[REDACTED] [@efpia.eu](#)
www.efpia.eu



For more information related to COVID-19 see: <https://efpia.eu/news-events/the-efpia-view/statements-press-releases/european-pharmaceutical-industry-response-to-coronavirus/>